Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

Share Price is delayed by 15 minutes
Get Live Data
5.80    -0.10 (-1.69%)
Bid:
5.70
Ask:
5.90
Spread: 0.20 (3.509%)
Market Cap: £14.92m
TEK Live PriceLast checked at - London Stock Exchange

Intraday TekCapital Share Chart

GenIP plc Schedule One

18 Sep 2024 07:58

RNS Number : 6650E
Tekcapital plc
18 September 2024
 

The information contained within this announcement is deemed by the Company (Companies House registration number 08873361) to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

18 September 2024

Tekcapital Plc

("Tekcapital")

 

GenIP plc Files Schedule One with the London Stock Exchange

("GenIP" or the "Company")

 

Tekcapital plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating valuable companies from investing in university technologies that can improve people's lives, is pleased to announce that its portfolio company GenIP has proposed an initial public offering ("IPO") on the AIM Market. GenIP has filed a Schedule One Form (see link below) with the London Stock Exchange regarding its proposed IPO.

Schedule One - GenIP plc - 07:30:00 18 Sep 2024 - News article | London Stock Exchange

GenIP's mission is to empower organisations to better evaluate and commercialise their technology discoveries by providing Generative Artificial Intelligence (GenAI) enhanced research reports assessing market potential and by utilising GenAI executive recruitment services to match technology organisations with experienced executives and business leaders.

 

The Company harnesses the power of GenAI using its bespoke software, Invention Evaluator®, and through its executive recruitment platform, VortechsTM, which together the Company believes will enable better, faster and more affordable technology commercialisation and investment decisions. This dual approach provides companies, research institutions and venture funds with comprehensive support, combining technical expertise with GenAI models to cost-effectively mitigate adverse selection and commercialise new discoveries.

 

Dr. Clifford Gross, Executive Chairman of Tekcapital said:

 

"We are excited to announce the forthcoming IPO of GenIP plc. A product of Tekcapital's technology incubator, GenIP's Invention Evaluator and Vortechs have been instrumental in commercialising numerous technological innovations, allowing them to develop from a clean piece of paper to operating companies and listed spinouts. Now, having forged commercial relationships with leading research institutions and successfully launched revenue-generating GenAI analytics services, we believe the Company is well placed for the next chapter of its growth story as a stand-alone Company providing GenAI services to the wider market. The new services were launched in September 2024 whereupon the Company received orders for 40 analytical assessments and three executive search assignments.

 

We are also thrilled to have Lord David Willetts, the current Chair of the UK Space Agency serve as Non-executive Chair of GenIP and Dr. David Gann, Oxford Professor and former Chairman of the UK Atomic Energy Authority serve as Non-Executive Director."

 

The AIM IPO is anticipated to be completed in the next few weeks. Tekcapital Plc, through its subsidiary Tekcapital Europe Limited, on consummation of the IPO is expected to own ~63% of the share capital of GenIP with an anticipated raise of approximately £1.5m.

 

About Tekcapital Plc

Tekcapital® creates value from investing in new, university-developed discoveries that can enhance people's lives. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.

 

About GenIP Plc

GenIP® provides generative artificial intelligence (GenAI) analytic services to help companies, research institutions and venture funds assess and commercialise new discoveries. GenIP combines expert human technical review with GenAI algorithms to provide insightful and verified services. To learn more about GenIP, please visit www.genip.ai (available as from Admission to AIM).

 

For further information about Tekcapital, please contact:

 

Tekcapital Plc 

Via Flagstaff

Clifford M. Gross, Ph.D. 

SP Angel Corporate Finance LLP

(Nominated Adviser and Broker)

+44 (0) 20 3470 0470 

Richard Morrison/Charlie Bouverat (Corporate Finance)/Abigail Wayne / Rob Rees (Corporate Broking)

 

 

Flagstaff Strategic and Investor Communications

+44 (0) 20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

LEI: 213800GOJTOV19FIFZ85

 

 

For further information regarding GenIP, please contact:

 

GenIP Plc

Melissa Cruz, CEO 

Via Redchurch Communications

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish

Tel: +44 (0) 207 628 3396

 

Novum Securities Limited (Broker) 

Jon Belliss

Tel: +44 (0)20 7399 9425

JBelliss@novumsecurities.com

 

 

Redchurch Communications (Financial PR)

 

LEI: 213800E6CFHS4IG69P89

John Casey

genip@weareredchurch.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGLGDCBUBDGSI
Date   Source Headline
27th May 20267:00 amRNSResults for Year Ended 31 December 2025
22nd May 20267:00 amRNSTekcapital takes stake in geothermal AI firm
21st May 20267:00 amRNSNew Orders
28th Apr 20267:00 amRNSStrategic Resale Alliance with Cardinal IP
18th Feb 20267:00 amRNSNotification of Major Holdings
10th Feb 20267:00 amRNSConditional Placing of £1.5 million
15th Jan 20267:00 amRNSCorporate Update
7th Jan 20267:00 amRNS-RPorfolio Company Update - Innovative Eyewear Inc
12th Dec 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear Inc
1st Dec 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
19th Nov 20257:00 amRNSPortfolio Company Update - Guident Corp
13th Nov 20257:00 amRNSInnovative Eyewear Q3 Unaudited Financial Results
13th Nov 20257:00 amRNSTrading Statement
10th Nov 20257:00 amRNS-RStrategic Alliance signed with Nexscient Inc
4th Nov 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
17th Oct 20254:15 pmRNSNotification of Major Holdings
13th Oct 20251:44 pmRNSPlacing of £0.37 Million
10th Oct 20257:00 amRNSNew Product Launch – Invention Validator
8th Oct 202510:53 amRNSReplacement - Unaudited Half-Yearly Report
7th Oct 20257:00 amRNS-RPortfolio Company Update Innovative Eyewear
6th Oct 20257:00 amRNSReplacement RNS: Half-year Report
30th Sep 20257:02 amRNSCommercial Strategy Update & New Products
30th Sep 20257:00 amRNSHalf-year Report
25th Sep 20257:00 amRNS-RPortfolio Company Update -Guident
24th Sep 20257:00 amRNSUnaudited Half Yearly Report
18th Sep 20257:00 amRNSPortfolio Company Update -Guident Proposed US IPO
10th Sep 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
29th Aug 20257:00 amRNS-RPortfolio Company Update Guident Corp
19th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
15th Aug 20257:00 amRNS-RPortfolio Company Update Innovative Eyewear Q2
13th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
6th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
25th Jul 20257:00 amRNSTrading Statement
24th Jul 20257:00 amRNS-RPortfolio Company Update - Guident Corp
21st Jul 20257:00 amRNS-RPortfolio Company Update- Innovative Eyewear
27th Jun 202512:39 pmRNSResult of AGM
19th Jun 20251:06 pmRNSNotification of Major Holdings
19th Jun 202511:07 amRNSHolding(s) in Company - Replacement
19th Jun 20257:00 amRNS-RPortfolio Company Update - Guident Corp
10th Jun 20257:00 amRNSContract Win
2nd Jun 20257:02 amRNSNotice of AGM
2nd Jun 20257:00 amRNSFinal Results Year Ended 31 December Notice of AGM
2nd Jun 20257:00 amRNSFundraising of £1.25 Million
29th May 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear Inc
23rd May 20257:00 amRNSFinal Results Year Ended 31 December 2024
16th May 20257:00 amRNS-RPortfolio Company Update - Guident Corp
12th May 20257:00 amRNSPortfolio Company Update:Guident Corp Proposed IPO
6th May 20257:00 amRNSPortfolio Company Update - Innovative Eyewear Inc.
28th Apr 20257:00 amRNSPortfolio Company Update - Innovative Eyewear Inc
24th Apr 20257:00 amRNSQ1 2025 Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.